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Abstract
Backgraund: Acute-phase response proteins (APRP), cytokines and hormones have been claimed to be an
independent prognostic factor of malignancies, however the basis for their association with prognosis remains
unexplained. We suggest that in colon malignancies, as similar to pancreatic and lung cancers, changes in APRP
are associated with angiogenesis.
Methods: C-reactive protein (CRP), albumin, IL-1a, IL-1β, IL-6, IL-8, IL-10, TNF-a, midkine, VEGF-A, VEGF-C, leptin,
adiponectin, and ghrelin serum levels are studied in 126 colon cancer patients and 36 healthy subjects.
Results: We found statistically significant difference and correlations between two groups. We found significantly
higher serum CRP, IL-1a, IL-1β, IL-6, IL-8, IL-10, TNF-a, VEGF-A, VEGF-C and leptin concentrations in patients relative
to controls (p < 0.001). We found lower levels of the serum albumin, midkine, adiponectin and ghrelin in patients
compared to control subjects (p < 0.001).
Conclusions: Cachexia in patients with colon cancers is associated with changes in APRP, cytokines and hormone
concentrations. These biomarkers and cachexia together have a direct relationship with accelerated angiogenesis.
This may lead to a connection between the outcomes in malignancies and the biomarkers.
Introduction
Cachexia due to cancer is one of the most frequent fea-
tures of malignancy [1], it accounts up to 30-50% of
cancer-related deaths in gastrointestinal tract malignan-
cies [2]. Cachexia due to cancer is a complex metabolic
disorder, including loss of adipose tissue due to lipolysis,
loss of skeletal muscle mass, elevation of resting energy
consumption, anorexia, and reduction of oral food
intake [3,4].
Despite intensive studies that have been conducted
thus far in this field, the multi-factorial pathological
mechanism of cancer-related cachexia has not been fully
exhibited, besides currently available treatment modal-
ities remain profoundly unsatisfactory [5]. Nevertheless,
it is well known that cytokine up-regulation contributes
to involuntary weight loss, which is a hallmark of can-
cer-related cachexia [6,7]. Although the catabolism is
mainly mediated by the effects of certain cytokines, such
as tumor necrosis factor-a (TNF-a), interleukin-1β
(IL-1β), and interleukin-6 (IL-6) [4,8], the mechanisms
associated with cancer related anorexia are still not elu-
cidated completely [9]. Previous studies concerning
cachexia in gastrointestinal cancer revealed that other
pro-inflammatory cytokines, such as IL-8 and, probably,
vascular endothelial growth factor-A (VEGF-A) and
midkine, might be involved in the process of cachexia
[10]. Also, the proteins such as cytokines, some hor-
mones and neuropeptides, which affect various central
mechanisms, are tightly related to the regulation of the
energy homeostasis [11]. These hormones include
adiponectin, ghrelin, and leptin [11,12].
Adiponectin is a member of a group of proteins
secreted from adipocytes [13] and its serum levels are
(5-30 μg/ml) higher in women compared with men
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body weight. Thus, low adiponectin levels are found in
obesity [14,15], and high levels are found in anorexia
nervosa [16] and during weight loss [17]. Several reports
have indicated association between low adiponectin
levels and increased risk of breast, endometrium, and
gastric cancers [18-20]. The mechanisms responsible for
regulation of adiponectin levels have not been fully
elucidated. Yet, recent data suggest down-regulation of
adiponectin by TNF-a, as well as by insulin [21]. The
hormone ghrelin is a 28 amino-acid peptide, unique by
the esterification of its third serine residue by n-octanoic
acid [22]. The major source of ghrelin is the stomach,
where it is synthesized in identical endocrine cells. The
peptide is a potent inducer of growth hormone (GH)
release, acting at the pituitary and hypothalamic
levels [23].
Ghrelin participates directly in hypothalamic regula-
tion of nutrition, it causes weight gain by reducing food
utilization, increasing food intake, and inhibiting leptin-
induced feeding reduction [24]. High ghrelin levels are
associated with various cachectic states, such as anorexia
nervosa and severe congestive heart failure [25].
Elevated levels were recently reported in lung cancer-
induced cachexia [26], and in a cohort of male patients
with mainly lung and prostate cancer [27].
Leptin is another member of the adipo-cytokines
family. It is produced mainly by differentiated adipocytes
and acts in the central nervous system as a suppresser for
food intake and stimulator of energy consumption [12].
Leptin plasma levels are reported to be higher in anorexia
nervosa patients [28], but lower in gastrointestinal [29],
and pancreatic cancer patients [30]. Association between
acute-phase response proteins (APRPs) and weight loss
in cancer-related cachexia has been reported only in pan-
creatic carcinoma and melanoma [31].
The aim of our study was to evaluate associations
between cachexia due to weight loss and APRPs (albu-
min, C-reactive protein (CRP)), cytokines (IL-1a,I L - 1 β,
IL-6, IL-10, TNF-a,I L - 8 ,V E G F - A ,V E G F - C ) ,m i d k i n e
and hormones (adiponectin, leptin and ghrelin) in a
population of newly diagnosed colon cancer patients.
Materials and methods
Patients
A total of 126 patients with colon cancer were enrolled
in our study. Exclusion criterias included: previous treat-
ment with chemotherapy, radiotherapy, or a major
operation history 6 months before recovery; brain
metastasis; second malignancy; acute or chronic infec-
tions; dysphagia; other primary cachectic states (i.e. con-
gestive pulmonary disease, cirrhosis); elevated bilirubin
or liver enzymes (> 2 of the upper normal reference
value); renal failure (creatinine > 2 mg/dl); history of
eating disorders; or gastrectomy.
Demographic clinical and anthropometric data were col-
lected during recovery period. All pathology reports were
reviewed, and data of the tumor histology were recorded.
Stage was defined according to the 1997 American Joint
Committee on Cancer Staging System [32].
We examined 41 cases of stage II cancers, 48 cases of
stage III, 37 cases of stage IV cancers. There were 54
females and 72 males, with a median age of 56 years
(range 38-74 years). We used sera from blood donors
considered healthy on the basis of routine blood tests to
obtain reference values in this study. The reference group
consisted of 38 individuals, 16 females and 22 males, with
a median age of 41 years (range 37-71 years).
Body mass index (BMI) was calculated as weight (kg)
divided by height (m
2), and cachexia was defined as
≥ 5% reduction in BMI at the time of recovery. The
study protocol was approved by the medical Ethics
Committee of Haseki Education and Research Hospital,
Istanbul, and was in accordance with the ethical stan-
dards formulated in the Helsinki Declaration of 1975.
Informed consent was obtained from all subjects.
Analytical Methods
The concentrations of all parameters in the examined
samples were measured in sera obtained from blood
drawn in the fasting state, clotted (15 min, room tem-
perature) and centrifuged (15 min, 1000 g). The serum
samples were then immediately frozen at -80°C until
further analysis (except albumin, CRP, and midkine).
The albumin concentrations were measured colorime-
trically as a complex of albumin with bromocresol blue
dye under acidic conditions. High-sensitive CRP was
determined by the immunonephelometry (Behring
Nephelometer II). Serum midkine concentrations were
assayed with indirect ELISA R&D Systems, USA) anti-
human midkine polyclonal antibodies were used. The
serum concentrations of IL-1a,I L - 1 β,I L - 6 ,I L - 8 ,a n d
TNF-a were assayed using a validated commercial ELISA
(Quantikine R&D Systems, Mineapolis). The IL-10 levels
were measured by using the Endogen Inc. assay (Cam-
bridge). The concentrations of VEGF-A and VEGF-C
were measured in duplicate with a commercially available
quantitative sandwich enzyme immunassay kit (R&D
Systems, USA). Adiponectin, ghrelin and leptin concen-
trations were determined using radioimmunassay kits
(Linco Research, St. Charles, Missouri).
Statistical Analysis
Data are presented as means ± SD. Comparisons were
performed with the non-parametric Mann-Whitney
U-test for continuous variables and with the c
2 test for
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mined using the log-rank test. Two-sided p values <
0.05 were considered statistically significant.
Results
There were no differences of median age between
patients with cancer and subjects in control group (p >
0.05). None of the parameters showed significant differ-
ence when they were compared by age between those
groups (p > 0.05). Plasma leptin levels showed no signif-
icant difference between genders (p > 0.05).
We found significantly higher serum CRP, IL-1a, IL-1β,
IL-6, IL-8, IL-10, TNF-a, VEGF-A, VEGF-C and leptin
concentrations in patients relative to controls (p < 0.001).
We found lower levels of the serum albumin, midkine,
adiponectin and ghrelin in patients compared to control
subjects (p < 0.001).
We found favourable correlation between BMI loss
and adiponectin levels (p < 0.01, r = 0.74). Also, we
found positive correlation between midkine and albu-
min; similarly between both BMI loss and plasma leptin
levels; and BMI loss and midkine.
There was significantly positive correlation between
BMI loss and VEGF-A; as well as VEGF-A and IL-1.
VEGF-A and IL-6 correlation was similarly statistically
significant; we also found favourable correlation between
adiponectin and BMI loss.
(respectively; p < 0.01, r = 0.58; p < 0.001, r = 0.69,
p < 0.01, r = 0.69; p < 0.01, r = 0.71; p < 0.01, r = 0.65,
p < 0.001, r = 0.73; p < 0.01, r = 0.61). The Concentra-
tions of all parameters in patients and controls were
shown in table 1.
Discussion
In our study, we analyzed the associations between acute-
phase response cytokines, pro-inflammatory cytokines,
cytokines, hormones and cancer related cachexia in a
population of newly diagnosed or newly recurrent,
untreated colon cancer. Systemic inflammation is a non
specific process of many cancer types. Association
between acute-phase related proteins and accelerated
weight loss has been described only in a few cancer types;
which are pancreatic, lung cancers and melanoma [31].
Decreased albumin concentrations are involved with
cachexia and are a common laboratuary feature in gastro-
intestinal cancers. Hypoalbuminemia has recently been
demonstrated to be a predictive factor of poor respon-
siveness [33,34]. Our results showing a weight-loss
dependent association with cachexia may support the
association of hypoalbuminemia and cachexia. The
decrease in transferring concentrations seems to be espe-
cially weight-loss dependent. The ongoing systemic
imflammatory response determined in terms of CRP con-
centrations has recently gained some interest, as an-easy-
to measure and well-standardized outcome predictor
[35,36]. Similar to substantial weight loss [10], an eleva-
tion in CRP concentration has been related to increased
extent of primary tumor and has been associated with
poor survival [35,36]. Our results may support the asso-
ciation of CRP concentrations and cancer related
cachexia. The association of CRP with the pro-angiogenic
environment may contribute to adverse effects together
with CRP elevation [37]. Our results reveal a positive cor-
relation between CRP and circulating IL-8, midkine,
which both have pro-angiogenic properties [38]. Similarly
CRP and VEGF correlation has been determined and
these results may further support this hypothesis. It is
also of interest that similar to CRP [35,36], circulating
midkine [10] and IL-8 [39] have been found to reflect
lymph node involvement in esophageal squamous cell
carcinoma. The concentrations of circulating IL-6 and
midkine, independently of the patients weight status, and
with Il-1, Il-8 and VEGF in cachectic cancer patients.
TNF-a, IL-1 and IL-6 are key cytokines involved in can-
cer-related cachexia. However, apart from IL-6, altera-
tions in their systemic levels are rarely detected [31]. As
experimental cytokine-directed anti-cachectic therapies
yielded moderate results [31], there is a need for finding
other mediators of cancer cachexia [5,31]. We found
midkine and VEGF to be independent predictors of
weight loss in patients with colon cancer. Our results
provide evidence for an association of midkine and VEGF
with systemic inflammation and malnutrition, supporting
a possible involvement of these cytokines in the patho-
genesis of cachexia. However, only the concentrations of
VEGF, and leptin but not midkine, are associated with
Table 1 Concentrations of all parameters in patients and
controls
Parametres Patients Controls p
Age (y) 43.5 ± 10.7 40.4 ± 11.3 > 0.05
Gender (F/M) 73/53 20/16
CRP (ng/ml) 9.8 ± 4.3 3.5 ± 2.1 < 0.001
Albumin (g/dl) 2.5 ± 1.2 4.4 ± 1.1 < 0.001
Midkine (ng/ml) 0.21 ± 0.034 0.36 ± 0.1 < 0.05
VEGF-A (pg/ml) 629.3 ± 205.6 309.4 ± 135.8 < 0.001
VEGF-C (pg/ml) 3428.1 ± 987.5 1736.9 ± 685.8 < 0.001
IL-1a (pg/ml) 785.7 ± 243.9 209.6 ± 102.3 < 0.001
IL-1β (pg/ml) 693.9 ± 305.7 276.9 ± 132.2 < 0.001
IL-6 (pg/ml) 109.6 ± 45.8 34.9 ± 29.7 < 0.0001
IL-8 (pg/ml) 78.6 ± 25.4 29.5 ± 19.6 < 0.001
IL-10 (pg/ml) 5.7 ± 1.9 2.3 ± 1.1 < 0.001
TNF-a (pg/ml) 28 ± 14 10 ± 7 < 0.001
Leptin (ng/ml) 47.6 ± 10.3 23.8 ± 11.4 < 0.001
Adiponectin (μg/ml) 4.3 ± 2.5 6.5 ± 1.4 < 0.001
Ghrelin (pmol/l) 178.5 ± 89.6 300.9 ± 57.3 < 0.001
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Midkine was related to inflammation and was correlated
with albumin concentration, while the associations were
not affected by cachexia. These together may further
indicate VEGF as rather a pro-cachectic cytokine, corro-
borating the findings of other authors demonstrating
VEGF associations with standard pro-cachectic cytokines.
IL-1 and IL-6 have been implicated in the regulation of
VEGF expression [40], while anti-TNF a treatment
(infliximab) has been shown to decrease serum VEGF
concentrations [41]. We found that VEGF correlated
with IL-1 and IL-6 exclusively in cachectic colon cancer
patiens. Although the involvement of midkine in inflam-
mation is well-documented [42], only a weak correlation
between midkine and CRP in cancer patients has been
reported [43].
Adiponectin levels are reported to be inversely corre-
lated with body weight. Thus, voluntary weight loss, as
well as anorexia nervosa, is associated with elevated adi-
ponectin levels [14,17,44]. However, in our study, we
found no correlation between decreased BMI and adipo-
nectin levels. Adiponectin levels are regulated mainly by
changes in the adipose tissue [44]. The lack of associa-
tion between adiponectin levels and weight loss may
simply reflect the preservation of adipose tissue. Recent
studies, which found inhibition of adiponectin secretion
from adipocytes by various cytokines, including TNF-a,
support our observations [21,45]. Thus, the lack of ele-
vation of adiponectin levels after cancer related
cachexia, may reflect altered regulation of adiponectin in
this condition. Interestingly, lower adiponectin levels
were also found in a cohort of cachectic patients with
very advanced stage of lung cancer compared with
healthy volunteers [46].
Elevated levels of total or active ghrelin in cancer
related cachexia have been reported in cohorts of mainly
male lung cancer patients [26].
In our study, we report elevated ghrelin levels in a
cohort of colon cancer patients. Notably, high levels of
ghrelin were also found among a significant number of
cachectic lung cancer patients [26]. Our results suggest
that measurement of ghrelin levels may have important
clinical implications in treating cancer related cachexia
syndrome. Although leptin levels are directly associated
with weight loss after fasting [47], associations between
leptin levels and cancer related cachexia are not yet fully
elucidated. Thus, lower leptin levels were found in
patients with gastrointestinal cancers, regardless of the
degree of weight loss [48]. However, association between
leptin levels and weight loss was noted in a cohort of
lung [49], and pancreatic cancer patients [29]. We also
found a correlation between leptin levels and cancer-
induced weight loss. Our results showing a weight-loss
dependent association with cachexia may support the
association of leptin with cachexia. Moreover, leptin
levels have positive correlation with IL-6 levels and CRP
in our study. This situation may explain high IL-6 levels
related with cancer progression and invasion. Pyrogenic
activity of this proinflammatory cytokine may responsi-
ble for cachexia and weight loss. In addition, IL-6 stimu-
lates to the synthesis of APRP. So, adiponectin, ghrelin
and leptin levels accelerated by APRP levels. Association
with between weight loss and levels of pro-inflammatory
cytokines, cytokins, APRP, adiponectin, ghrelin and lep-
tin leves have not been explained yet. We suggested that
adiponectin, ghrelin and leptin are tightly regulated the
energy homeostasis such as cytokines, which affect var-
ious central mechanisms [11]. Our study revealed an
association between cytokine and pro-inflammatory cell
concentrations and APRP in patients with colon cancer.
In our study, there is an association between these para-
meters and levels of these hormones, which confirm our
hypothesis.
In conclusion, our results provide evidence for an
association between colon cancer related cachexia and
changes in the concentrations of APRPs, cytokines and
hormones. More studies should be performed to con-
firm this association between cachexia and APRP, cyto-
kines, and hormones in patients with colon cancer, as
well as in other cancer types.
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